UBS Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $548M | Sell |
3,930,216
-849,463
| -18% | -$119M | 0.08% | 248 |
|
|
2025
Q4 | $587M | Sell |
4,779,679
-368,006
| -7% | -$44.7M | 0.1% | 204 |
|
|
2025
Q3 | $571M | Buy |
5,147,685
+586,863
| +13% | +$66.7M | 0.09% | 211 |
|
|
2025
Q2 | $506M | Sell |
4,560,822
-65,400
| -1% | -$6.96M | 0.09% | 221 |
|
|
2025
Q1 | $518M | Sell |
4,626,222
-257,398
| -5% | -$26.6M | 0.1% | 206 |
|
|
2024
Q4 | $451M | Buy |
4,883,620
+745,697
| +18% | +$67.1M | 0.08% | 221 |
|
|
2024
Q3 | $347M | Sell |
4,137,923
-358,822
| -8% | -$27.4M | 0.08% | 249 |
|
|
2024
Q2 | $309M | Buy |
4,496,745
+282,831
| +7% | +$18.9M | 0.08% | 250 |
|
|
2024
Q1 | $309M | Buy |
4,213,914
+657,604
| +18% | +$50.6M | 0.08% | 249 |
|
|
2023
Q4 | $288M | Buy |
3,556,310
+451,397
| +15% | +$35.1M | 0.09% | 234 |
|
|
2023
Q3 | $233M | Sell |
3,104,913
-252,070
| -8% | -$19.4M | 0.08% | 243 |
|
|
2023
Q2 | $259M | Buy |
3,356,983
+1,269,205
| +61% | +$101M | 0.09% | 240 |
|
|
2023
Q1 | $173M | Sell |
2,087,778
-743,154
| -26% | -$61.6M | 0.06% | 297 |
|
|
2022
Q4 | $243M | Buy |
2,830,932
+603,988
| +27% | +$47.8M | 0.09% | 231 |
|
|
2022
Q3 | $137M | Sell |
2,226,944
-614,137
| -22% | -$38.7M | 0.06% | 320 |
|
|
2022
Q2 | $176M | Buy |
2,841,081
+555,442
| +24% | +$34.4M | 0.07% | 284 |
|
|
2022
Q1 | $136M | Sell |
2,285,639
-1,086,698
| -32% | -$69.5M | 0.05% | 411 |
|
|
2021
Q4 | $245M | Sell |
3,372,337
-348,539
| -9% | -$24M | 0.07% | 291 |
|
|
2021
Q3 | $260M | Buy |
3,720,876
+531,873
| +17% | +$37.4M | 0.08% | 240 |
|
|
2021
Q2 | $220M | Sell |
3,189,003
-125,744
| -4% | -$8.4M | 0.07% | 273 |
|
|
2021
Q1 | $214M | Sell |
3,314,747
-199,739
| -6% | -$12.9M | 0.07% | 279 |
|
|
2020
Q4 | $205M | Sell |
3,514,486
-213,285
| -6% | -$12.9M | 0.07% | 274 |
|
|
2020
Q3 | $236M | Sell |
3,727,771
-165,508
| -4% | -$11.5M | 0.09% | 224 |
|
|
2020
Q2 | $300M | Sell |
3,893,279
-261,536
| -6% | -$20M | 0.13% | 175 |
|
|
2020
Q1 | $311M | Sell |
4,154,815
-1,163,541
| -22% | -$80.4M | 0.15% | 149 |
|
|
2019
Q4 | $346M | Buy |
5,318,356
+647,904
| +14% | +$42.2M | 0.12% | 175 |
|
|
2019
Q3 | $296M | Sell |
4,670,452
-127,834
| -3% | -$8.36M | 0.11% | 176 |
|
|
2019
Q2 | $324M | Buy |
4,798,286
+23,980
| +0.5% | +$1.58M | 0.12% | 171 |
|
|
2019
Q1 | $310M | Buy |
4,774,306
+149,925
| +3% | +$9.96M | 0.13% | 174 |
|
|
2018
Q4 | $289M | Sell |
4,624,381
-1,069,424
| -19% | -$74.7M | 0.13% | 173 |
|
|
2018
Q3 | $440M | Buy |
5,693,805
+1,134,309
| +25% | +$85.7M | 0.17% | 137 |
|
|
2018
Q2 | $323M | Buy |
4,559,496
+325,216
| +8% | +$23M | 0.14% | 170 |
|
|
2018
Q1 | $319M | Sell |
4,234,280
-755,036
| -15% | -$60M | 0.14% | 172 |
|
|
2017
Q4 | $357M | Sell |
4,989,316
-18,732
| -0.4% | -$1.42M | 0.15% | 160 |
|
|
2017
Q3 | $406M | Buy |
5,008,048
+508,590
| +11% | +$38.9M | 0.19% | 125 |
|
|
2017
Q2 | $318M | Sell |
4,499,458
-430,696
| -9% | -$28.7M | 0.16% | 154 |
|
|
2017
Q1 | $335M | Sell |
4,930,154
-706,426
| -13% | -$49.7M | 0.18% | 135 |
|
|
2016
Q4 | $404M | Sell |
5,636,580
-610,274
| -10% | -$45.4M | 0.22% | 107 |
|
|
2016
Q3 | $494M | Buy |
6,246,854
+1,199,565
| +24% | +$97.4M | 0.29% | 67 |
|
|
2016
Q2 | $421M | Sell |
5,047,289
-524,637
| -9% | -$46.6M | 0.26% | 71 |
|
|
2016
Q1 | $512M | Sell |
5,571,926
-1,549,669
| -22% | -$140M | 0.34% | 47 |
|
|
2015
Q4 | $721M | Buy |
7,121,595
+1,201,840
| +20% | +$125M | 0.47% | 25 |
|
|
2015
Q3 | $581M | Sell |
5,919,755
-437,821
| -7% | -$48.6M | 0.41% | 30 |
|
|
2015
Q2 | $744M | Buy |
6,357,576
+546,492
| +9% | +$59.7M | 0.49% | 18 |
|
|
2015
Q1 | $570M | Sell |
5,811,084
-1,545,064
| -21% | -$157M | 0.39% | 34 |
|
|
2014
Q4 | $693M | Buy |
+7,356,148
| New | +$761M | 0.48% | 21 |
|
Other funds holding GILD
VCM
VPM
UBS Group's GILD Position: Q1 2026 in Review
UBS Group reduced its Gilead Sciences (GILD) stake by 18% in Q1 2026, selling an estimated $119M and leaving 3,930,216 shares worth $548M. The position accounts for 0.08% of the portfolio, ranked #248.
UBS Group first reported a position in GILD in Q4 2014 and has held it in 46 quarters since. The position peaked at $744M in Q2 2015. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- UBS Group held 3,930,216 shares of Gilead Sciences worth $548M as of Q1 2026.
- UBS Group sold 849,463 Gilead Sciences shares in Q1 2026, an estimated $119M.
- Gilead Sciences made up 0.08% of UBS Group's portfolio in Q1 2026, its #248 holding.
- UBS Group first reported a position in Gilead Sciences in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Gilead Sciences position peaked at $744M in Q2 2015.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.